Skip to content

Abstract 8604: Histone Lactylation-Mediated Serpina3n Transcription Promotes Pathological Cardiac Hypertrophy via LRP1/β-Catenin Signaling

Nov 2026 · Circulation · 0 citations

Abstract

Background: Pathological cardiac hypertrophy is a major risk factor for heart failure, yet its underlying mechanisms remain incompletely understood. Recent evidences implicated that lactate induced histone lactylation especially histone H3 lysine 18 lactylation (H3K18la) participates in cardiovascular diseases, but its functional role in cardiac hypertrophy requires further elucidation. Methods: Transverse aortic constriction (TAC) was performed in mice, and neonatal rat cardiomyocytes (NRCMs) were treated with angiotensin II (Ang II) to model pathological hypertrophy. H3K18la levels were assessed in the in-vivo,in-vitro and clinical samples. Pharmacological inhibition and siRNA targeted lactate dehydrogenase A (LDHA) were used to modulate H3K18la. The epigenetic targets were identified by Cleavage Under Targets and Tagmentation (CUT&Tag). Gene-knockout mice and adeno-associated virus 9 (AAV9)-mediated overexpression were applied to manipulate target gene expression in TAC model. Liquid Chromatography-Mass Spectrometer (LC/MS), Co-Immunoprecipitation (Co-IP) and RNA sequencing (RNA-seq) were used to clarify the specific molecular mechanisms underlying downstream signaling pathways. Results: Both lactate and H3K18la were significantly elevated in hypertrophic hearts. Inhibiting H3K18la by reducing the LDHA activity or expression could alleviate myocardial hypertrophy and protect heart function. CUT&Tag analysis showed that H3K18la was enriched at the Serpina3n promoter. The Serpina3n expression and secretion was upregulated during development of cardiac hypertrophy and downregulated while the H3K18la was inhibited. Diminished expression of Serpina3n could ameliorate the hypertrophy, whereas increased its expression reversely exacerbate the hypertrophic remodeling. Mechanistically, Serpina3n was secreted and directly bound to the membrane receptor LRP1, leading to β-catenin activation. Finally, the pro-hypertrophic effect of Serpina3n could abolished by suppressing the LRP1 and β-catenin, respectively. Conclusions: This study identifies a novel H3K18la/Serpina3n/LRP1/β-catenin cascade that drives pathological cardiac hypertrophy. Targeting this specific axis may provide new therapeutic strategies for hypertrophic heart disease and heart failure.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.